In this issue:
NEW definition of high-risk multiple myeloma
Expert panel consensus on outpatient administration of teclistamab and talquetamab
Updates to NCCN Clinical Practice Guidelines
2025 EHA-EMN recommendations for the management of myeloma
TGA registrations
New registrations
Myeloma medications under review
AusPARs
PBAC recommendations
Upcoming PBAC agenda
Funded CAR T-cell therapy coming…but when?
Global status of myeloma drugs not approved in Australia
2025 IMS Annual Meeting
Conferences & Workshops
Please login below to download this issue (PDF)